MARKET

CNSY

CNSY

Cerenome, Inc
NASDAQ
2.410
+0.700
+40.94%
Suspension 10:49 11/03 EST
OPEN
1.700
PREV CLOSE
1.710
HIGH
4.250
LOW
1.700
VOLUME
19.51M
TURNOVER
--
52 WEEK HIGH
18.89
52 WEEK LOW
1.485
MARKET CAP
18.29M
P/E (TTM)
-0.5456
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CNSY last week (1026-1030)?
Weekly Report · 1d ago
Cerenome Completes Enrollment In Phase 2 ReSPECT-GBM Trial Of REYOBIQ In Recurrent Glioblastoma; Topline Data Expected Mid-2027
Benzinga · 5d ago
Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day
Benzinga · 10/27 11:33
Weekly Report: what happened at CNSY last week (1019-1023)?
Weekly Report · 10/26 09:01
Cerenome announces new dual mechanism of action for REYOBIQ
TipRanks · 10/21 13:11
Cerenome Presents New Preclinical Data At 16th Biennial Rivkin Ovarian Cancer Research Symposium Regarding Immunomodulatory Properties Of REYOBIQ
Benzinga · 10/21 11:31
Weekly Report: what happened at CNSY last week (1012-1016)?
Weekly Report · 10/19 09:01
New Strong Sell Stocks for October 15th
NASDAQ · 10/15 07:47
More
About CNSY
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.

Webull offers Cerenome, Inc. (USA) stock information, including NASDAQ: CNSY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNSY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNSY stock methods without spending real money on the virtual paper trading platform.